(Q48721651)

14 February 2018

title

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome (English)

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

dexamethasone suppression test

26 October 2022

main subject

schizophrenia

0 references

0 references

dexamethasone

1 reference

based on heuristic

inferred from title

schizophrenic psychology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

author name string

DeQuardo J

3

1 reference

14 February 2018

Meador-Woodruff JH

5

1 reference

14 February 2018

R. Tandon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

C. Mazzara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

J. DeQuardo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

K. A. Craig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

J. H. Meador-Woodruff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

R. Goldman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

J. F. Greden

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676605

26 October 2022

language of work or name

English

0 references

publication date

1 May 1991

1 reference

14 February 2018

15 May 1991

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1676605

full work available at URL

26 October 2022

https://api.elsevier.com/content/article/PII:000632239190353N?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

https://api.elsevier.com/content/article/PII:000632239190353N?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

26 October 2022

published in

Biological Psychiatry

1 reference

14 February 2018

volume

29

1 reference

14 February 2018

page(s)

953-964

1 reference

14 February 2018

issue

10

1 reference

14 February 2018

Depression dexamethasone nonsuppression and negative symptoms in schizophrenia

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test, schizophrenia and movement disorder

26 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test in positive and negative schizophrenia

26 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Does the dexamethasone suppression test have clinical utility in psychiatry?

26 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test

26 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Associations among dexamethasone non-suppression and TRH-induced hormonal responses: increased specificity for melancholia?

26 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The nature and prevalence of depression in chronic schizophrenic in-patients

26 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The Dexamethasone Suppression Test in depression, in schizophrenia, and during experimental stress

26 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry

26 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Pituitary-adrenal disinhibition in depression: marker of a subtype with characteristic clinical features and response to treatment?

26 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Deficit and nondeficit forms of schizophrenia: the concept

26 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

NEUROTRANSMITTER STUDIES OF NEUROENDOCRINE PATHOLOGY IN DEPRESSION

26 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility

26 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test in depression and other psychiatric illness.

26 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

HPA axis hyperactivity and recovery from functional psychoses

26 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in depression

26 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Abnormal dexamethasone suppression test results in chronic schizophrenic patients

26 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients

26 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility

26 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Development of a Rating Scale for Primary Depressive Illness

26 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test and residual schizophrenia

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Comparison of early and delayed inpatient dexamethasone suppression tests

26 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in newly hospitalized schizophrenic patients

26 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels

26 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in affective illnesses and schizophrenia: relationship with psychotic symptoms

26 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test: use of two different dexamethasone doses

26 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test in schizophrenic patients: report from India

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

DST and schizophrenic symptomatology

26 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

TRH test and DST in schizoaffective mania, mania, and schizophrenia

26 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Drugs and the DST: need for a reappraisal

26 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Diagnostic utility of the dexamethasone suppression test

26 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test and negative symptoms of schizophrenia

26 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The Chestnut Lodge follow-up study. I. Follow-up methodology and study sample

26 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

DST in chronic schizophrenia

26 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The diagnostic distribution of dexamethasone non-suppressors.

26 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions

26 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The metyrapone test in schizophrenic patients and healthy subjects.

26 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in residual schizophrenia with depression

26 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay

26 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia

26 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Decreased beta-adrenergic receptors in the leukocytes of depressed patients

26 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test as a discriminator among subtypes of psychotic patients

26 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients

26 October 2022

58

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Abnormal dexamethasone suppression test in type II schizophrenia

26 October 2022

59

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The dexamethasone suppression test in schizophrenia

26 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Hypothalamic-pituitary-adrenal axis activity in depressive illness. Its relationship to classification

26 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The effect of diagnosis and age on the DST: a metaanalytic approach

26 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

"Negative symptoms": conceptual and methodological problems

26 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test and noradrenergic function in affective and schizophrenic disorders

26 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Research diagnostic criteria: rationale and reliability

26 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Pretreatment DST and Hypothalamic-Pituitary-Adrenocortical Function in Depressed Patients and Comparison Groups

26 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The prediction of outcome in schizophrenia. I. Characteristics of outcome.

26 October 2022

69

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

26 October 2022

70

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Positive and negative symptoms in schizophrenia and the Dexamethasone Suppression Test.

26 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Neuroendocrine dysfunction in schizophreniform disorder: correlation with six-month clinical outcome

26 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone nonsuppression in chronic schizophrenia

26 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment

26 October 2022

78

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Specificity of plasma HVA response to dexamethasone in psychotic depression

26 October 2022

79

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls

26 October 2022

80

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

Dexamethasone suppression test and urinary MHPG X SO4 determination in depressive disorders

26 October 2022

81

1 reference

https://api.crossref.org/works/10.1016/0006-3223(91)90353-N

26 October 2022

Identifiers

1 reference

14 February 2018

1 reference

14 February 2018